<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02770040</url>
  </required_header>
  <id_info>
    <org_study_id>HREC/14/Austin/595</org_study_id>
    <nct_id>NCT02770040</nct_id>
  </id_info>
  <brief_title>Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis</brief_title>
  <acronym>PREDICT-UC</acronym>
  <official_title>PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis - A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austin Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Austin Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify whether an Accelerated or Intensified Infliximab
      induction regimen is superior to Standard induction in Acute Severe Ulcerative Colitis in an
      open label multi-centre randomised controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colectomy free survival</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Day 14</time_frame>
    <description>defined as a reduction in the Lichtiger score below 10 with a decrease of at least 3 points</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Absence of clinical response at day 7
Relapse between day 7 and 90 (defined as a Lichtiger score increase of at least 3 points from the previous value that lasts for at least 3 consecutive days and leads to treatment modification)
A severe adverse event leading to treatment interruption
Colectomy by day 90
Death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in daily Lichtiger score</measure>
    <time_frame>From day 0 to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroid free remission</measure>
    <time_frame>Day 90</time_frame>
    <description>defined as a Mayo disease activity index score ≤2 with an endoscopic subscore ≤1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission rate</measure>
    <time_frame>Day 90</time_frame>
    <description>defined as a Mayo endoscopic subscore of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic remission rate</measure>
    <time_frame>12 months</time_frame>
    <description>defined as a Mayo endoscopic subscore of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colectomy free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Intensified Infliximab Induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infliximab 10mg/kg at Week 0 and Week 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Accelerated Infliximab Induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infliximab 5mg/kg at Week 0, Week 1 and Week 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Infliximab Induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infliximab 5mg/kg at Week 0, Week 2 and Week 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused</description>
    <arm_group_label>Intensified Infliximab Induction</arm_group_label>
    <arm_group_label>Accelerated Infliximab Induction</arm_group_label>
    <arm_group_label>Standard Infliximab Induction</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years old

          -  Diagnosis of Ulcerative Colitis

          -  Acute Severe Colitis according to the Truelove and Witt's Criteria

          -  Steroid refractory according to the Oxford Criteria

        Exclusion Criteria:

          -  Participant unable to consent for themselves

          -  Indication for immediate surgery (acute abdomen, perforation of the bowel,
             haemorrhage)

          -  Crohn's disease

          -  Participants with enteric infection confirmed on stool microscopy, culture or toxin

          -  Haemodynamic instability (mean arterial pressure &lt;60) and not responsive to fluids

          -  Participants with clinically significant Cytomegalovirus infection (positive inclusion
             bodies, immunohistochemistry and signs of viraemia such as fever and abnormal liver
             function tests)

          -  Participants who are pregnant or currently breast-feeding

          -  Participants with current malignancy, excluding basal cell carcinoma

          -  Participants with flat low or high grade colonic dysplasia; sporadic adenomas
             permitted

          -  Participants with serious co-morbidities including: Immunodeficiency; Myocardial
             infarction or acute stroke within the last 3 months; Moderate or severe heart failure
             (New York Heart Association class III or IV); Active or suspected tuberculosis; Renal
             failure; Hepatic failure; other severe infections

          -  Participants with history of hypersensitivity to infliximab or infliximab biosimilar

          -  Participants who have received other immunosuppressive agents including but not
             limited to: Anti-TNF therapies within 3 months of screening (Infliximab, Infliximab
             biosimilar, Golimumab, Etanercept, Certolizumab or Adalimumab); Anti-integrins
             (Vedolizumb, Etrolizumab) within 4 months of screening; Calcineurin inhibitors
             (Cyclosporine, Tacrolimus) within 4 weeks of screening; T or B cell depleters
             (Rituximab, Alemtuzumab) within 12 months of screening; other investigational agents
             (eg. Ustekinumab) within 6 months of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter De Cruz, MBBS PhD FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austin Health, Melbourne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew C Choy, MBBS BMedSci FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austin Health, Melbourne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter De Cruz, MBBS PhD FRACP</last_name>
    <phone>+61 3 9496 6845</phone>
    <email>Peter.DeCruz@austin.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew C Choy, MBBS BMedSci FRACP</last_name>
    <phone>+61 3 9496 5000</phone>
    <email>Matthew.Choy@austin.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Boyd, RN BHS</last_name>
      <phone>+613 9496 6845</phone>
      <email>Kristy.BOYD@austin.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2016</study_first_posted>
  <last_update_submitted>July 2, 2016</last_update_submitted>
  <last_update_submitted_qc>July 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Austin Health</investigator_affiliation>
    <investigator_full_name>Dr Peter De Cruz</investigator_full_name>
    <investigator_title>Head of Inflammatory Bowel Disease Unit</investigator_title>
  </responsible_party>
  <keyword>Acute Severe Ulcerative Colitis</keyword>
  <keyword>Steroid Refractory Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

